User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regenerationtherapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.
Exosome hair therapy involves injecting stem cell-derived exosomes into the scalp to boost hair follicle regeneration and repair. Exosomes, which are not stem cells but products of them, contain bioactive chemicals and specific growth factors that promote new blood vessel formation, increase cell proliferation, reduce inflammation, and improve tissue repair, all crucial for hair health.
Exercise, especially leg workouts, combined with finasteride and minoxidil, may enhance hair regrowth. Cold exposure, like cold showers, might further boost results.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
The conversation is a guide on treating hair loss, discussing finasteride and dutasteride to lower DHT, minoxidil for growth, ketoconazole shampoo for scalp health, and dermarolling for regeneration. RU58841 is mentioned as a DHT blocker but not recommended due to safety concerns.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation discusses whether sunlight exposure affects hair growth or loss, with mixed anecdotes and theories but no clear consensus. Some suggest moderate sunlight can benefit hair by providing vitamin D, while others doubt its effectiveness compared to treatments like Minoxidil or finasteride.
The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.
The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
Bryan Johnson shared his hair loss treatment, which mainly relies on minoxidil and finasteride. Some users are skeptical of his results, while others appreciate his efforts in anti-aging and hair loss research.
The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
